Axatilimab + Azacitidine

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Atypical Chronic Myeloid Leukemia

Conditions

Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm

Trial Timeline

Aug 2, 2024 → Oct 31, 2028

NCT ID

NCT06523556

About Axatilimab + Azacitidine

Axatilimab + Azacitidine is a phase 1/2 stage product being developed by Incyte for Atypical Chronic Myeloid Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06523556. Target conditions include Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm.

What happened to similar drugs?

1 of 8 similar drugs in Atypical Chronic Myeloid Leukemia were approved

Approved (1) Terminated (0) Active (7)

✅DuloxetineEli LillyApproved

🔄CrovalimabChugai PharmaceuticalPhase 3

🔄Teriparatide 20 mcgEli LillyPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄IptacopanNovartisPhase 3

🔄Iptcaopan 200 mgNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06523556	Phase 1/2	Recruiting	Aug 2, 2024	Oct 31, 2028	Atypical Chronic Myeloid Leukemia

Competing Products

18 competing products in Atypical Chronic Myeloid Leukemia

See all competitors

Product	Company	Stage	Hype Score
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Crovalimab	Chugai Pharmaceutical	Phase 3	44
Duloxetine	Eli Lilly	Approved	43
Teriparatide 20 mcg	Eli Lilly	Phase 3	40
Baricitinib	Eli Lilly	Pre-clinical	26
Ravulizumab	AstraZeneca	Pre-clinical	33
Eculizumab	AstraZeneca	Phase 3	40
Iptacopan	Novartis	Phase 3	44
Iptcaopan 200 mg	Novartis	Phase 3	47
Iptacopan	Novartis	Phase 3	47
Ropeginterferon Alfa-2B	PharmaEssentia	Phase 2	42
CCX168	Amgen	Phase 2	27
Tazemetostat + Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 1/2	39
Cemdisiran	Alnylam Pharmaceuticals	Phase 2	24
cemdisiran + Placebos	Alnylam Pharmaceuticals	Phase 2	24
Gemcitabine + Paxalisib	Pacific Biosciences	Phase 2	32
Apatinib Mesylate	Brain Biotech	Pre-clinical	23
azurin-derived cell-penetrating peptide p28	Brain Biotech	Phase 1	19